The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

BACKGROUND: Tanimilast is a novel and selective inhaled inhibitor of phosphodiesterase-4 in advanced clinical development for chronic obstructive pulmonary disease (COPD). Tanimilast is known to exert prominent anti-inflammatory activity when tested in preclinical experimental models as well as in h...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Hoang Oanh, Salvi, Valentina, Tiberio, Laura, Facchinetti, Fabrizio, Govoni, Mirco, Villetti, Gino, Civelli, Maurizio, Barbazza, Ilaria, Gaudenzi, Carolina, Passari, Mauro, Schioppa, Tiziana, Sozio, Francesca, Del Prete, Annalisa, Sozzani, Silvano, Bosisio, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092691/
https://www.ncbi.nlm.nih.gov/pubmed/35538539
http://dx.doi.org/10.1186/s12967-022-03402-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092691/
https://www.ncbi.nlm.nih.gov/pubmed/35538539
http://dx.doi.org/10.1186/s12967-022-03402-x

Ejemplares similares